Rucaparib is an orally active and potent inhibitor of polyadenosine diphosphate ribose polymerase (PARP). This drug is known for its potent inhibition of PARP1, with a Ki value of 1.4 nM for PARP1 and also shows affinity for eight other PARP domains.

How to use Rucaparib?

Rucaparib is a targeted drug for cancers with specific genetic mutations, and proper use is the key to clarifying efficacy and reducing adverse effects. This section will explain in detail how to use it and how to adjust it.

Recommended dosage and administration

The standard dose of Rucaparib is 600 mg orally twice daily (two 300 mg tablets), with a total daily dose not exceeding 1200 mg. The duration of the medication is not restricted by diet and can be taken before or after meals. If the patient misses a dose, no follow-up dose is required, and the next dose should be taken at the scheduled time. If vomiting occurs, no additional dose adjustment is required.

Dose adjustment and treatment continuity

During treatment, if the patient experiences serious adverse effects (such as hematotoxicity or elevated liver enzymes), treatment should be temporarily interrupted or the dose reduced should be reduced according to the doctor's recommendation. Treatment should be continued until disease progression or intolerable toxicity. Patients with prostate cancer may require concomitant hormone therapy or bilateral orchiectomy to enhance outcomes.

Adjusting the dose appropriately and adhering to the standard medication can help reduce the risk of side effects while controlling the condition. Patients need to have regular follow-up visits and communicate with the medical team in a timely manner.

Precautions for the use of Rucaparib

The correct use of Rucaparib involves not only dose control, but also the potential risks and drug safety of special populations. The following will help patients and caregivers get a complete picture of what to look out for.

Monitoring and management of adverse reactions

Common adverse reactions include fatigue, nausea, anemia, abnormal liver function, etc. Patients with ovarian cancer are of particular concern for thrombocytopenia and neutropenia, while patients with prostate cancer may have a rash or constipation. If you have severe symptoms, such as difficulty breathing or a persistent high fever, you should seek medical attention immediately. Your doctor may relieve your symptoms by adjusting the dose or suspending treatment.

Medication restrictions for special populations

Rucaparib is contraindicated in pregnant women because it may cause irreversible damage to the fetus; Breastfeeding women should wait at least two weeks after stopping the drug before returning to breastfeeding. Men or women who wish to have children should use strict contraception during treatment and for three months after stopping the drug. The safety profile of children and patients with severe hepatic and renal insufficiency is unclear and requires careful evaluation before deciding whether to use the drug.

Understanding adverse reactions and medication restrictions in special populations can help patients avoid potential risks and determine the safety of the treatment process.

Storage environment in Rucaparib

The stability of the drug directly affects its efficacy, and Rucaparib has strict requirements for storage conditions. The following details how to store the drug properly.

Temperature and humidity control

Rucaparib should be stored at 15°C to 30°C away from high temperatures or freezing. Extreme temperatures can cause drug ingredients to break down. At the same time, it should be kept dry to avoid moisture and deterioration of the tablets due to humid conditions. It is advisable to keep the medication in its original packaging in a well-ventilated cabinet.

Protection from light and package integrity

Drugs should be kept away from direct sunlight, as light exposure may damage their chemical structure. The seal of the original packaging prevents contamination and the tablets should never be transferred to other containers. If you notice that the packaging is damaged or the tablet is discolored, you should stop using it immediately and contact a professional for disposal.

Following the scientific storage method, the drug activity can be maintained to the maximum extent and the patient can be provided with safe and effective treatment guarantee.